Cite

HARVARD Citation

    Perche, P. et al. (2023). Abrocitinib: A New FDA-Approved Drug for Moderate-to-Severe Atopic Dermatitis. Annals of pharmacotherapy. 57 (1), pp. 86-98. [Online]. 
  
Back to record